Symbols / BDRX Stock $3.81 +3.40% Biodexa Pharmaceuticals Plc

Healthcare • Biotechnology • United Kingdom • NCM
BDRX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Stephen Anthony Stamp
Exch · Country NCM · United Kingdom
Market Cap 2.47M
Enterprise Value 1.19T
Income -6.38M
Sales —
FCF (ttm) -1.00M
Book/sh 34.26
Cash/sh 8,534,000.00
Employees 11
Insider 10d —
IPO Dec 07, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E inf
PEG —
P/S —
P/B 0.11
P/C —
EV/EBITDA -138,821.05
EV/Sales —
Quick Ratio 1.43
Current Ratio 2.03
Debt/Eq 0.54
LT Debt/Eq —
EPS (ttm) -3.41
EPS next Y 0.00
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2020-09-09
Earnings (prior) 2020-09-09
ROA -32.79%
ROE -64.72%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 648.31K
Shs Float 275.36B
Insider Own 0.07%
Instit Own 10.26%
Short Float 2.64%
Short Ratio 0.01
Short Interest 17.09K
52W High 96.50
vs 52W High -96.06%
52W Low 2.86
vs 52W Low 33.04%
Beta 1.16
Impl. Vol. —
Rel Volume 0.02
Avg Volume 778.66K
Volume 19.02K
Target (mean) $35.90
Tgt Median $35.90
Tgt Low $35.90
Tgt High $35.90
# Analysts 1
Recom None
Prev Close $3.68
Price $3.81
Change 3.40%
About

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$35.91
Mean price target
2. Current target
$3.80
Latest analyst target
3. DCF / Fair value
$-27.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.80
Low
$35.91
High
$35.91
Mean
$35.91

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-02-08 init Ladenburg Thalmann — → Buy $8
News
RSS: Latest BDRX news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
-100.00%
0.38
-45.49%
0.70
Operating Revenue
0.00
0.00
-100.00%
0.38
-45.49%
0.70
Cost Of Revenue
3.96
-27.15%
5.44
+33.69%
4.07
-20.43%
5.11
Reconciled Cost Of Revenue
3.96
-27.15%
5.44
+33.69%
4.07
-20.43%
5.11
Gross Profit
-3.96
+27.15%
-5.44
-47.50%
-3.69
+16.46%
-4.41
Operating Expense
4.68
+24.51%
3.76
-13.08%
4.33
-4.25%
4.52
Selling General And Administration
4.84
+27.50%
3.79
-12.64%
4.34
-4.40%
4.54
Selling And Marketing Expense
—
—
—
—
General And Administrative Expense
4.84
+27.50%
3.79
-12.64%
4.34
-4.40%
4.54
Other Gand A
4.84
+27.50%
3.79
-12.64%
4.34
-4.40%
4.54
Other Operating Expenses
-0.15
-390.32%
-0.03
-121.43%
-0.01
+36.36%
-0.02
Total Expenses
8.64
-6.02%
9.20
+9.58%
8.39
-12.83%
9.63
Operating Income
-8.64
+6.02%
-9.20
-14.79%
-8.01
+10.28%
-8.93
Total Operating Income As Reported
-8.64
+6.02%
-9.20
-14.79%
-8.01
+10.28%
-8.93
EBITDA
-6.07
-9.19%
-5.56
+22.36%
-7.16
+11.51%
-8.09
Normalized EBITDA
-8.37
+4.68%
-8.78
-14.78%
-7.65
+10.65%
-8.56
Reconciled Depreciation
0.19
-25.59%
0.25
-10.25%
0.28
-17.49%
0.34
EBIT
-6.26
-7.67%
-5.81
+21.90%
-7.44
+11.75%
-8.44
Total Unusual Items
2.30
-28.65%
3.22
+560.78%
0.49
+4.06%
0.47
Total Unusual Items Excluding Goodwill
2.30
-28.65%
3.22
+560.78%
0.49
+4.06%
0.47
Special Income Charges
—
—
—
0.00
Impairment Of Capital Assets
—
—
—
0.00
Net Income
-6.38
-11.43%
-5.73
+19.07%
-7.08
+7.54%
-7.66
Pretax Income
-6.49
-8.53%
-5.98
+20.12%
-7.49
+11.82%
-8.49
Net Non Operating Interest Income Expense
-0.14
-7100.00%
0.00
-95.24%
0.04
+275.00%
-0.02
Interest Expense Non Operating
0.23
+38.79%
0.17
+302.44%
0.04
-22.64%
0.05
Net Interest Income
-0.14
-7100.00%
0.00
-95.24%
0.04
+275.00%
-0.02
Interest Expense
0.23
+38.79%
0.17
+302.44%
0.04
-22.64%
0.05
Interest Income Non Operating
0.09
-46.71%
0.17
+101.20%
0.08
+186.21%
0.03
Interest Income
0.09
-46.71%
0.17
+101.20%
0.08
+186.21%
0.03
Other Income Expense
2.30
-28.65%
3.22
+560.78%
0.49
+4.06%
0.47
Gain On Sale Of Security
2.30
-28.65%
3.22
+560.78%
0.49
+4.06%
0.47
Tax Provision
-0.10
+58.00%
-0.25
+38.42%
-0.41
+51.20%
-0.83
Tax Rate For Calcs
0.00
-61.30%
0.00
-22.91%
0.00
-44.66%
0.00
Tax Effect Of Unusual Items
0.04
-72.39%
0.13
+409.37%
0.03
-42.42%
0.05
Net Income Including Noncontrolling Interests
-6.38
-11.43%
-5.73
+19.07%
-7.08
+7.54%
-7.66
Net Income From Continuing Operation Net Minority Interest
-6.38
-11.43%
-5.73
+19.07%
-7.08
+7.54%
-7.66
Net Income From Continuing And Discontinued Operation
-6.38
-11.43%
-5.73
+19.07%
-7.08
+7.54%
-7.66
Net Income Continuous Operations
-6.38
-11.43%
-5.73
+19.07%
-7.08
+7.54%
-7.66
Net Income Discontinuous Operations
—
—
—
—
Normalized Income
-8.64
+1.92%
-8.81
-16.88%
-7.54
+6.67%
-8.08
Net Income Common Stockholders
-6.38
-11.43%
-5.73
+19.07%
-7.08
+7.54%
-7.66
Otherunder Preferred Stock Dividend
—
—
—
0.00
Diluted EPS
-0.50
+99.90%
-500.00
+95.00%
-10,000.00
+98.71%
-775,000.00
Basic EPS
-0.50
+99.90%
-500.00
+95.00%
-10,000.00
+98.71%
-775,000.00
Basic Average Shares
0.11
+1007.63%
0.01
+213.68%
0.00
-74.44%
0.01
Diluted Average Shares
0.11
+1007.63%
0.01
+213.68%
0.00
-74.44%
0.01
Diluted NI Availto Com Stockholders
-6.38
-11.43%
-5.73
+19.07%
-7.08
+7.54%
-7.66
Line Item Trend 2022-12-31
Total Assets
5.53
Current Assets
4.69
Cash Cash Equivalents And Short Term Investments
2.84
Cash And Cash Equivalents
2.84
Cash Financial
2.84
Receivables
1.48
Accounts Receivable
0.33
Other Receivables
0.30
Taxes Receivable
0.85
Prepaid Assets
0.38
Total Non Current Assets
0.84
Net PPE
0.83
Gross PPE
2.46
Accumulated Depreciation
-1.63
Properties
0.00
Buildings And Improvements
0.05
Machinery Furniture Equipment
0.15
Other Properties
2.26
Leases
0.05
Goodwill And Other Intangible Assets
0.01
Goodwill
0.00
Other Intangible Assets
0.01
Total Liabilities Net Minority Interest
2.36
Current Liabilities
1.90
Payables And Accrued Expenses
1.25
Payables
0.43
Accounts Payable
0.34
Other Payable
0.02
Current Accrued Expenses
0.82
Total Tax Payable
0.08
Current Debt And Capital Lease Obligation
0.16
Current Debt
0.00
Current Capital Lease Obligation
0.16
Current Deferred Liabilities
0.20
Current Deferred Revenue
0.20
Other Current Liabilities
0.09
Total Non Current Liabilities Net Minority Interest
0.46
Long Term Debt And Capital Lease Obligation
0.46
Long Term Debt
—
Long Term Capital Lease Obligation
0.46
Other Non Current Liabilities
-0.00
Stockholders Equity
3.16
Common Stock Equity
3.16
Capital Stock
0.11
Common Stock
0.11
Share Issued
5.42
Ordinary Shares Number
5.42
Treasury Shares Number
0.00
Additional Paid In Capital
83.67
Retained Earnings
-135.34
Gains Losses Not Affecting Retained Earnings
53.00
Other Equity Adjustments
53.00
Total Equity Gross Minority Interest
3.16
Total Capitalization
3.16
Working Capital
2.79
Invested Capital
3.16
Total Debt
0.62
Capital Lease Obligations
0.62
Net Tangible Assets
3.16
Tangible Book Value
3.16
Current Provisions
0.21
Foreign Currency Translation Adjustments
0.00
Other Equity Interest
1.72
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-5.59
+54.40%
-12.26
-79.62%
-6.83
+3.15%
-7.05
Cash Flow From Continuing Operating Activities
-5.59
+54.40%
-12.26
-79.62%
-6.83
+3.15%
-7.05
Net Income From Continuing Operations
-6.38
-11.43%
-5.73
+19.07%
-7.08
+7.54%
-7.66
Depreciation Amortization Depletion
0.19
-25.59%
0.25
-10.25%
0.28
-17.49%
0.34
Depreciation
0.19
-25.40%
0.25
-10.00%
0.28
-17.65%
0.34
Amortization Cash Flow
0.00
-50.00%
0.00
-33.33%
0.00
+0.00%
0.00
Depreciation And Amortization
0.19
-25.59%
0.25
-10.25%
0.28
-17.49%
0.34
Amortization Of Intangibles
0.00
-50.00%
0.00
-33.33%
0.00
+0.00%
0.00
Other Non Cash Items
0.14
+7100.00%
-0.00
+95.24%
-0.04
-275.00%
0.02
Stock Based Compensation
0.17
-39.93%
0.28
+910.71%
0.03
-77.24%
0.12
Asset Impairment Charge
0.37
0.00
-100.00%
0.08
-61.84%
0.21
Deferred Tax
-0.10
+58.00%
-0.25
+38.42%
-0.41
+51.20%
-0.83
Deferred Income Tax
-0.10
+58.00%
-0.25
+38.42%
-0.41
+51.20%
-0.83
Operating Gains Losses
-2.40
+25.33%
-3.21
-561.86%
-0.48
-6.59%
-0.46
Gain Loss On Investment Securities
-2.30
+28.65%
-3.22
-560.78%
-0.49
-4.06%
-0.47
Net Foreign Currency Exchange Gain Loss
-0.13
-3350.00%
0.00
0.00
+100.00%
-0.00
Gain Loss On Sale Of PPE
0.03
+625.00%
0.00
+100.00%
0.00
-85.71%
0.01
Change In Working Capital
1.72
+145.93%
-3.74
-7524.49%
-0.05
-109.42%
0.52
Change In Receivables
2.63
+144.00%
-5.97
-1736.99%
0.36
+5114.29%
0.01
Change In Payables And Accrued Expense
-0.91
-140.78%
2.24
+1181.64%
-0.21
-158.15%
0.36
Change In Payable
-0.91
-140.78%
2.24
+1181.64%
-0.21
-158.15%
0.36
Change In Other Working Capital
—
—
-0.21
-231.85%
0.16
Investing Cash Flow
-0.58
+2.51%
-0.60
-125.66%
-0.27
-20.45%
-0.22
Cash Flow From Continuing Investing Activities
-0.58
+2.51%
-0.60
-125.66%
-0.27
-20.45%
-0.22
Net PPE Purchase And Sale
0.02
+277.78%
-0.01
+59.09%
-0.02
+47.62%
-0.04
Purchase Of PPE
-0.00
+77.78%
-0.01
+65.38%
-0.03
+58.06%
-0.06
Sale Of PPE
0.02
0.00
-100.00%
0.00
-80.00%
0.02
Capital Expenditure
-0.69
+10.72%
-0.77
-194.30%
-0.26
-324.19%
-0.06
Net Business Purchase And Sale
—
—
—
—
Purchase Of Business
—
—
—
—
Net Intangibles Purchase And Sale
-0.69
+9.93%
-0.77
-222.78%
-0.24
0.00
Purchase Of Intangibles
-0.69
+9.93%
-0.77
-222.78%
-0.24
0.00
Net Other Investing Changes
—
—
-0.08
+61.84%
-0.21
Financing Cash Flow
13.04
+52.38%
8.56
-16.32%
10.23
+21657.45%
0.05
Cash Flow From Continuing Financing Activities
13.04
+52.38%
8.56
-16.32%
10.23
+21657.45%
0.05
Net Issuance Payments Of Debt
-0.70
-384.08%
0.24
+230.32%
-0.19
-5.62%
-0.18
Issuance Of Debt
—
0.43
0.00
0.00
Repayment Of Debt
-0.25
-32.26%
-0.19
+1.06%
-0.19
-5.62%
-0.18
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
-0.25
-32.26%
-0.19
+1.06%
-0.19
-5.62%
-0.18
Net Long Term Debt Issuance
-0.70
-384.08%
0.24
+230.32%
-0.19
-5.62%
-0.18
Short Term Debt Issuance
—
0.43
0.00
0.00
Net Short Term Debt Issuance
—
0.43
0.00
0.00
Net Common Stock Issuance
13.75
+65.41%
8.31
-20.28%
10.43
+4190.95%
0.24
Cash Dividends Paid
0.00
0.00
0.00
0.00
Changes In Cash
6.87
+259.58%
-4.30
-237.22%
3.13
+143.42%
-7.22
Effect Of Exchange Rate Changes
0.00
0.00
0.00
0.00
Beginning Cash Position
1.67
-72.05%
5.97
+110.54%
2.84
-71.80%
10.06
End Cash Position
8.53
+411.32%
1.67
-72.05%
5.97
+110.54%
2.84
Free Cash Flow
-6.28
+51.81%
-13.04
-83.88%
-7.09
+0.30%
-7.11
Common Stock Issuance
13.75
+65.41%
8.31
-20.28%
10.43
+4190.95%
0.24
Interest Paid CFF
-0.01
0.00
+100.00%
-0.01
+27.78%
-0.02
Interest Received CFI
0.09
-48.86%
0.18
+141.10%
0.07
+151.72%
0.03
Issuance Of Capital Stock
13.75
+65.41%
8.31
-20.28%
10.43
+4190.95%
0.24
Taxes Refund Paid
0.71
+448.06%
0.13
-84.73%
0.84
+24.63%
0.68
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category